Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy

被引:47
作者
Cao, Lei [1 ]
Zhu, Yuqin [1 ]
Wang, Weiju [2 ]
Wang, Gaoxiong [1 ]
Zhang, Shuaishuai [3 ]
Cheng, Hongwei [4 ,5 ]
机构
[1] Quanzhou Womens & Childrens Hosp, Dept Pathol, Quanzhou, Peoples R China
[2] Qingyuan Maternal & Child Hlth Hosp, Dept Pathol, Qingyuan, Peoples R China
[3] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Peoples R China
[4] Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China
[5] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen, Peoples R China
关键词
tumor chemotherapy; drug resistance; tumor microenvironment; nanomedical strategy; combination therapy; CANCER STEM-CELLS; MULTIDRUG-RESISTANCE; BREAST-CANCER; CO-DELIVERY; MOLECULAR-MECHANISMS; P-GLYCOPROTEIN; IN-VITRO; NANOPARTICLES; THERAPY; CHEMORESISTANCE;
D O I
10.3389/fbioe.2021.798882
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Drug resistance is the most significant causes of cancer chemotherapy failure. Various mechanisms of drug resistance include tumor heterogeneity, tumor microenvironment, changes at cellular levels, genetic factors, and other mechanisms. In recent years, more attention has been paid to tumor resistance mechanisms and countermeasures. Nanomedicine is an emerging treatment platform, focusing on alternative drug delivery and improved therapeutic effectiveness while reducing side effects on normal tissues. Here, we reviewed the principal forms of drug resistance and the new possibilities that nanomaterials offer for overcoming these therapeutic barriers. Novel nanomaterials based on tumor types are an excellent modality to equalize drug resistance that enables gain more rational and flexible drug selectivity for individual patient treatment. With the emergence of advanced designs and alternative drug delivery strategies with different nanomaterials, overcome of multidrug resistance shows promising and opens new horizons for cancer therapy. This review discussed different mechanisms of drug resistance and recent advances in nanotechnology-based therapeutic strategies to improve the sensitivity and effectiveness of chemotherapeutic drugs, aiming to show the advantages of nanomaterials in overcoming of drug resistance for tumor chemotherapy, which could accelerate the development of personalized medicine.
引用
收藏
页数:17
相关论文
共 136 条
[1]  
Abolhoda A, 1999, CLIN CANCER RES, V5, P3352
[2]   Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages [J].
Alsaab, Hashem O. ;
Sau, Samaresh ;
Alzhrani, Rami M. ;
Cheriyan, Vino T. ;
Polin, Lisa A. ;
Vaishampayan, Ulka ;
Rishi, Arun K. ;
Iyer, Arun K. .
BIOMATERIALS, 2018, 183 :280-294
[3]   Gold nanoparticles: opportunities and challenges in nanomedicine [J].
Arvizo, Rochelle ;
Bhattacharya, Resham ;
Mukherjee, Priyabrata .
EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (06) :753-763
[4]   pH and Redox Dual Responsive Nanoparticle for Nuclear Targeted Drug Delivery [J].
Bahadur, Remant K. C. ;
Thapa, Bindu ;
Xu, Peisheng .
MOLECULAR PHARMACEUTICS, 2012, 9 (09) :2719-2729
[5]   Unravelling cancer stem cell potential [J].
Beck, Benjamin ;
Blanpain, Cedric .
NATURE REVIEWS CANCER, 2013, 13 (10) :727-738
[6]   Studying clonal dynamics in response to cancer therapy using high-complexity barcoding [J].
Bhang, Hyo-eun C. ;
Ruddy, David A. ;
Radhakrishna, Viveksagar Krishnamurthy ;
Caushi, Justina X. ;
Zhao, Rui ;
Hims, Matthew M. ;
Singh, Angad P. ;
Kao, Iris ;
Rakiec, Daniel ;
Shaw, Pamela ;
Balak, Marissa ;
Raza, Alina ;
Ackley, Elizabeth ;
Keen, Nicholas ;
Schlabach, Michael R. ;
Palmer, Michael ;
Leary, Rebecca J. ;
Chiang, Derek Y. ;
Sellers, William R. ;
Michor, Franziska ;
Cooke, Vesselina G. ;
Korn, Joshua M. ;
Stegmeier, Frank .
NATURE MEDICINE, 2015, 21 (05) :440-U207
[7]   Cellular and molecular mechanisms in cancer immune escape: a comprehensive review [J].
Bhatia, Alka ;
Kumar, Yashwant .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (01) :41-62
[8]   Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date [J].
Bobo, Daniel ;
Robinson, Kye J. ;
Islam, Jiaul ;
Thurecht, Kristofer J. ;
Corrie, Simon R. .
PHARMACEUTICAL RESEARCH, 2016, 33 (10) :2373-2387
[9]   Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1 [J].
Brown, LM ;
Cowen, RL ;
Debray, C ;
Eustace, A ;
Erler, JT ;
Sheppard, FCD ;
Parker, CA ;
Stratford, IJ ;
Williams, KJ .
MOLECULAR PHARMACOLOGY, 2006, 69 (02) :411-418
[10]   Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors [J].
Butt, Adeel Masood ;
Amin, Mohd Cairul Iqbal Mohad ;
Katas, Haliza ;
Murad, Nor Azian Abdul ;
Jamal, Rahman ;
Kesharwani, Prashant .
MOLECULAR PHARMACEUTICS, 2016, 13 (12) :4179-4190